智通财经网·2025-09-22 11:32Core Viewpoint - The company announced that its subsidiary, Guangzhou Baiyunshan Guanghua Pharmaceutical Co., Ltd., has registered the Phase II clinical trial for its pediatric Xiaochaihu granules, focusing on the treatment of pediatric gastrointestinal colds [1] Group 1: Clinical Trial Information - The clinical trial is designed as a randomized, double-blind, parallel-controlled, multi-center Phase II study [1] - The primary focus of the trial is to evaluate the efficacy and safety of pediatric Xiaochaihu granules in treating pediatric gastrointestinal colds (邪犯少阳证) [1] Group 2: Regulatory Approvals - Guanghua Pharmaceutical received the Drug Clinical Trial Approval Notice from the National Medical Products Administration in May 2023 [1] - Following the approval, the company completed the ethical review and obtained the ethical approval to proceed with the Phase II clinical trial [1]